hwney2004 1. hwney2004 2 safe harbor statement* this report contains statements which address such...
TRANSCRIPT
HWNEY2004 2
Safe harbor statement*Safe harbor statement*
This report contains statements which address such key issues as Akzo Nobel’s growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements, including but not limited to the “Outlook for 2005”, should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to price fluctuations, currency fluctuations, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more complete discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the Company’s website www.akzonobel.com.
* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.
HWNEY2004 3
Hans Wijers, CEO
Creating a platform for growthCreating a platform for growth
2004 Results Press ConferenceFebruary 4, 2005
HWNEY2004 4
2004 2004 –– actions to strengthen the Company actions to strengthen the Company paid offpaid off
Akzo Nobel tackled challenges with accelerated pace of change
Robust performance 2004 – actions paying off
2005 – facing the future from a position of strength
HWNEY2004 5
Robust performance in the face of Robust performance in the face of headwindheadwind• Pharma: sales down 9%, but margins held steady thanks
to restructuring and benefits of new alliances
• Coatings: autonomous growth 5%, steady ROS and higher ROI despite steep rise in raw material costs
• Chemicals: quantum leap in ROI, strong operating profit growth from continuing operations
• Divestment program achieved EUR 1 billion proceeds
• Operating leverage due to aggressive restructuring – cost lowered by EUR 150 million compared to 2003
HWNEY2004 6
Creating the platforms for growthCreating the platforms for growth
Pharma – ready for renewed top-line growth
Coatings – expanding #1 position
Chemicals – further focused platform
HWNEY2004 8
Net income substantially up Net income substantially up
EUR mln or % 2004 2003 Δ%
Sales 12,688 13,051 (3)
EBIT* 1,210 1,347 (10)
Net income excl. nonrec. 770 811 (5)
Net income 856 602 42
Ratio or EUR
ROS* 9.5 10.3
EPS 3.00 2.11
* Excluding nonrecurring items
HWNEY2004 9
Outperformance against 2004 outlookOutperformance against 2004 outlook
EUR mln or % 2004 2003** Δ%
Sales 12,688 13,051 (3)
EBIT* 1,210 1,259 (4)
Net income excl. nonrec. 770 741 4
Net income 856 542 58
ROS* 9.5 9.6
* Excluding nonrecurring items** Excluding initial asenapine payment
HWNEY2004 10
Autonomous growth 2%Autonomous growth 2%
EUR bln Sales Δ%
12.712.7 (3)
Pharma 3.23.2 (9)
Chemicals 4.34.3 1*
Coatings 5.25.2 2
2004
Growth + 2%
Currencies – 3%
Divestments/acquisitions – 2%
Total – 3%
* Ongoing operations
HWNEY2004 11
Operating income downOperating income down
EUR mln EBIT Δ%
1,2101,210 (10)
Pharma 522522 (14)*
Chemicals 354354 21**
Coatings 421421 2
2004
Pensions
+ 4%
Currencies
– 4%
Divestments/acquisitions
– 2%
Performance
– 2%
Total
– 4%
Pfizer
– 6%
Total
– 10%
* Excluding asenapine.** Ongoing operations.Excluding nonrecurring items.
HWNEY2004 12
• Organon – turning point for top-line growth
• Diosynth – overcapacity
• Intervet – good results
Pharma – margin aggressively defended; Pharma – margin aggressively defended;
benefiting from strategic realignments benefiting from strategic realignments
HWNEY2004 13
Excluding nonrecurring items; Q-4 dark top part concerns asenapine special benefit.
Pharma – margin protection program Pharma – margin protection program mitigating effect top-line declinemitigating effect top-line decline
EUR mln
Sales EBIT
Sales EBIT
0
300
600
900
Q-1 Q-2 Q-3 Q-4
0
50
100
150
200
250
300
350
20032004
HWNEY2004 14
Coatings – volume growth and improved Coatings – volume growth and improved efficiency offset rising raw materials costs efficiency offset rising raw materials costs • Steep increase in raw material costs in second half
• Autonomous growth 5%, mainly Asia Pacific and U.S., 32% of sales now from emerging markets
• ROS held steady at 8%, ROI improved to 20.5%
• Marine & Protective and Powder Coatings led growth
• Decorative Coatings – improved performance from cost savings
• Car Refinishes – major worldwide restructuring set to pay off in 2005
HWNEY2004 15
Excluding nonrecurring items
Sales EBIT
EUR mln Sales EBIT
0
500
1.000
1.500
Q-1 Q-2 Q-3 Q-4
0
100
200
20032004
Coatings – raw materials impact 2H, priority Coatings – raw materials impact 2H, priority
to obtain higher selling prices in 2005to obtain higher selling prices in 2005
HWNEY2004 16
• Benefits of cost savings programs combine with improved
business conditions to lift performance
• Continued operations – autonomous growth 5%;
operating income up 21%
• Steeply rising raw material and energy prices – increasing
pressure on margins
• EUR 1 bln divestment program – completed
Chemicals – best performance in yearsChemicals – best performance in years
HWNEY2004 17
Excluding nonrecurring items.Dark top part concerns Catalysts, Phosphorus Chemicals and Coating Resins.
Sales EBIT
EUR mln Sales EBIT
0
250
500
750
1.000
1.250
Q-1 Q-2 Q-3 Q-4
0
25
50
75
100
125
20032004
Chemicals – superior performance from Chemicals – superior performance from continuing operationscontinuing operations
HWNEY2004 18
Restructuring in mature markets – Restructuring in mature markets – growth in Asia Pacificgrowth in Asia Pacific
Number of employees
Restructuring 2,650Restructuring 2,650Divestments 1,610Divestments 1,610
GrowthGrowth1,1301,130
December 31, 2003: 64,580December 31, 2003: 64,580
December 31, 2004: 61,450December 31, 2004: 61,450
HWNEY2004 19
Positive impact of nonrecurring itemsPositive impact of nonrecurring items
• Net nonrecurring gain of EUR 86 million
– divestments
– restructuring and impairment charges
– antitrust cases
– settlement of Remeron® cases
HWNEY2004 20
Strong financial position, dividend Strong financial position, dividend maintainedmaintainedDecember 31; EUR bln 2004 2003
Working capital 2.2 2.6
Equity 3.2 2.6
Net borrowings 1.1 2.4
EUR or %
Dividend 1.20 1.20
Payout ratio 45 42
HWNEY2004 21
Q-4 operational performanceQ-4 operational performance
• Q-4 earnings lower
• Autonomous growth of 4%
• Operating income down 42%
• Good operational performance
• Pharmaceuticals performance in line with expectations
• Coatings impacted by raw material costs
• Chemicals good
HWNEY2004 23
Strategic review Chemicals – conclusionsStrategic review Chemicals – conclusions
• Focus portfolio on selected market segments meeting the following criteria:
– Leading position and significant size
– Competitive advantage and opportunity to grow
– Sustainable above average financial performance
– Good internal fit
HWNEY2004 24
Commitment to 5 core businesses with Commitment to 5 core businesses with clear prospects for profitable clear prospects for profitable leadership leadership • Pulp & Paper Chemicals
Pulp Bleaching and Paper Chemicals for global pulp & paper industry
• Polymer ChemicalsOrganic Peroxides and additives for polymer producers and processors around the world
• SurfactantsSurfactants for cleaning, agro, mining and petroleum applications
• Functional ChemicalsHigh value added specialties, intermediates and derivatives
• Base ChemicalsIntegrated Energy, Salt and Chlorine chain
HWNEY2004 25
Businesses to be divestedBusinesses to be divested
• Ink & Adhesive Resins
• Oleochemicals
• Salt Specialties
• PVC Additives
• Solar Salt Australia
• Methyl Amines / Choline Chloride
• Others
Total 2004 sales of about EUR 750 mln
HWNEY2004 26
Clarity of directionClarity of direction
• Challenging restructuring necessary to secure a
solid foundation for Akzo Nobel Chemicals
• A clear commitment to support profitable growth
in strategic areas
• Manage divestments and rationalization
in an efficient and responsible manner
HWNEY2004 28
We enter 2005 in excellent shape, facing We enter 2005 in excellent shape, facing the future from a position of strengththe future from a position of strength• Demonstrate Pharma pipeline progress
• Active consideration of opportunities to expand leadership positions
• Push volume growth and price increases to mitigate raw materials cost pressures
• Execute new divestment program and reap benefits of further restructuring
HWNEY2004 29
2005 – c2005 – cautiously optimisticautiously optimistic
• Top-line growth across portfolio
• Continued external pressure on margins
– raw material and energy prices
– currencies
• Costs to support future launches from Pharma pipeline
– defending margins vs. R&D and pre-marketing costs
Aspiring to achieve net income within range of Aspiring to achieve net income within range of 20042004 excluding nonrecurring items
HWNEY2004 31
Q-4 operational performanceQ-4 operational performance
• Q-4 earnings lower
• Autonomous growth of 4%
• Operating income down 42%
• Good operational performance
• Pharmaceuticals performance in line with expectations
• Coatings impacted by raw material costs
• Chemicals good
HWNEY2004 32
Q-4 earnings – at a first glanceQ-4 earnings – at a first glance
Q-4; EUR mln or % 2004 2003 Δ%
Sales 3,040 3,111 (2)
EBIT* 254 441 (42)
Net income excl. nonrec 165 268 (38)
Net income 90 105 (14)
* Excluding nonrecurring items
HWNEY2004 33
Q-4 earnings – excluding asenapine Q-4 earnings – excluding asenapine paymentpaymentQ-4; EUR mln or % 2004 2003** Δ%
Sales 3,040 3,111 (2)
EBIT* 254 353 (28)
Net income excl. nonrec 165 198 (17)
Net income 90 35 157
* Excluding nonrecurring items** Excluding initial asenapine payment
HWNEY2004 34
Autonomous growth 4%Autonomous growth 4%
Q-4, EUR bln Sales Δ%
3.03.0 (2)
Pharma 0.80.8 (9)
Chemicals 1.01.0 6*
Coatings 1.21.2 7
2004
Growth + 4%
Currencies – 3%
Divestments/acquisitions – 3%
Total – 2%
* Ongoing operations
HWNEY2004 35
Operating income down 42%Operating income down 42%
Q-4, EUR mln EBIT Δ%
254254 (42)
Pharma 119119 (40)*
Chemicals 8888 24**
Coatings 5656 (32)
* Excluding asenapine.** Ongoing operations.Excluding nonrecurring items.
2004
Pensions + 3%
Performance – 20%
Pfizer – 20%
Divestments/acquisitions – 3%
Currencies – 2%
Total – 42%